Takeda Pharmaceutical Company Limited (TAK) Financial Ratios
26 years of historical data (2000–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↓
9.13
↑+140% vs avg
5yr avg: 3.80
30Y Low0.3·High11.2
P/FCF
↑
9.77
↑+9398% vs avg
5yr avg: 0.10
30Y Low0.0·High0.5
P/B Ratio
↓
1.04
↑+14076% vs avg
5yr avg: 0.01
30Y Low0.0·High0.0
ROE
↓
2.8%
-13% vs avg
5yr avg: 3.2%
30Y Low-6%·High18%
Debt/EBITDA
↓
3.67
↓-14% vs avg
5yr avg: 4.27
30Y Low0.0·High12.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TAK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Takeda Pharmaceutical Company Limited trades at 39.6x earnings, 14066% above its 5-year average of 0.3x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 79%. On a free-cash-flow basis, the stock trades at 9.8x P/FCF, 9398% above the 5-year average of 0.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $48.8B | $59.4B | $47.7B | $43.9B | $51.7B | $45.2B | $57.5B | $47.5B | $39.4B | $38.4B | $37.2B |
| Enterprise Value | $75.5B | $4.36T | $4.18T | $4.43T | $3.90T | $3.54T | $3.73T | $4.50T | $5.09T | $729.5B | $862.6B |
| P/E Ratio → | 39.56 | 0.29 | 0.44 | 0.30 | 0.16 | 0.20 | 0.15 | 1.07 | 0.59 | 0.21 | 0.32 |
| P/S Ratio | 1.65 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 |
| P/B Ratio | 1.04 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 |
| P/FCF | 9.77 | 0.07 | 0.06 | 0.19 | 0.15 | 0.05 | 0.07 | 0.11 | 0.20 | 0.15 | 0.25 |
| P/OCF | 7.94 | 0.06 | 0.05 | 0.06 | 0.05 | 0.04 | 0.06 | 0.07 | 0.12 | 0.10 | 0.14 |
P/E links to full P/E history page with 30-year chart
TAK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Takeda Pharmaceutical Company Limited's enterprise value stands at 9.1x EBITDA, 140% above its 5-year average of 3.8x. The Healthcare sector median is 14.2x, placing the stock at a 36% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.91 | 0.91 | 1.04 | 0.97 | 0.99 | 1.17 | 1.37 | 2.43 | 0.41 | 0.50 |
| EV / EBITDA | 9.13 | 3.26 | 3.78 | 5.16 | 3.38 | 3.39 | 3.49 | 6.58 | 11.24 | 1.72 | 2.64 |
| EV / EBIT | 21.30 | 7.62 | 9.30 | 8.87 | 6.29 | 5.90 | 8.79 | 51.02 | 28.95 | 3.21 | 5.72 |
| EV / FCF | — | 5.40 | 4.88 | 18.80 | 11.36 | 3.78 | 4.81 | 9.96 | 26.18 | 2.92 | 5.78 |
TAK Profitability
Margins and return-on-capital ratios measuring operating efficiency
Takeda Pharmaceutical Company Limited earns an operating margin of 12.0%. Operating margins have expanded from 5.0% to 12.0% over the past 3 years, signaling improving operational efficiency. ROE of 2.8% is modest. ROIC of 3.7% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.1% | 51.1% | 65.5% | 66.4% | 69.1% | 69.0% | 68.9% | 66.9% | 68.5% | 72.0% | 67.7% |
| Operating Margin | 12.0% | 12.0% | 7.5% | 5.0% | 12.2% | 12.9% | 15.9% | 3.1% | 9.8% | 13.7% | 9.0% |
| Net Profit Margin | 4.3% | 4.3% | 2.4% | 3.4% | 7.9% | 6.4% | 11.8% | 1.3% | 5.2% | 10.6% | 6.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.8% | 2.8% | 1.5% | 2.1% | 5.3% | 4.2% | 7.6% | 0.9% | 3.0% | 9.4% | 5.8% |
| ROA | 1.4% | 1.4% | 0.7% | 1.0% | 2.3% | 1.8% | 2.9% | 0.3% | 1.2% | 4.4% | 2.8% |
| ROIC | 3.7% | 3.7% | 2.3% | 1.5% | 3.8% | 3.8% | 4.2% | 0.8% | 2.4% | 6.6% | 4.6% |
| ROCE | 4.6% | 4.6% | 2.8% | 1.8% | 4.4% | 4.2% | 4.7% | 0.9% | 2.8% | 7.6% | 5.2% |
TAK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Takeda Pharmaceutical Company Limited carries a Debt/EBITDA ratio of 3.7x, which is moderately leveraged (14% above the sector average of 3.2x). Net debt stands at $4.3T ($4.9T total debt minus $597.6B cash). Interest coverage of just 1.5x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.63 | 0.63 | 0.65 | 0.67 | 0.69 | 0.76 | 0.90 | 1.08 | 1.11 | 0.49 | 0.59 |
| Debt / EBITDA | 3.67 | 3.67 | 4.09 | 5.64 | 3.79 | 4.16 | 4.34 | 7.45 | 12.70 | 2.33 | 3.50 |
| Net Debt / Equity | — | 0.55 | 0.60 | 0.60 | 0.61 | 0.62 | 0.71 | 0.94 | 0.98 | 0.34 | 0.42 |
| Net Debt / EBITDA | 3.22 | 3.22 | 3.74 | 5.11 | 3.33 | 3.35 | 3.43 | 6.51 | 11.15 | 1.63 | 2.52 |
| Debt / FCF | — | 5.32 | 4.82 | 18.61 | 11.21 | 3.73 | 4.74 | 9.86 | 25.98 | 2.77 | 5.53 |
| Interest Coverage | 1.51 | 1.51 | 3.27 | 470.12 | 5.30 | 4.90 | 3.24 | 60.51 | 3.65 | 7.12 | 6.49 |
TAK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.27x means Takeda Pharmaceutical Company Limited can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.70x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.11x to 1.27x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.27 | 1.27 | 1.01 | 1.11 | 0.97 | 1.21 | 1.53 | 1.13 | 1.21 | 1.46 | 0.92 |
| Quick Ratio | 0.70 | 0.70 | 0.52 | 0.58 | 0.57 | 0.81 | 1.10 | 0.79 | 0.82 | 1.17 | 0.76 |
| Cash Ratio | 0.24 | 0.24 | 0.16 | 0.20 | 0.22 | 0.41 | 0.57 | 0.30 | 0.29 | 0.51 | 0.28 |
| Asset Turnover | — | 0.31 | 0.32 | 0.28 | 0.29 | 0.27 | 0.25 | 0.26 | 0.15 | 0.43 | 0.40 |
| Inventory Turnover | 1.67 | 1.67 | 1.30 | 1.18 | 1.26 | 1.30 | 1.32 | 1.43 | 0.67 | 2.33 | 2.47 |
| Days Sales Outstanding | — | 67.24 | 57.78 | 59.72 | 61.78 | 74.08 | 92.76 | 87.05 | 130.38 | 88.40 | 93.73 |
TAK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Takeda Pharmaceutical Company Limited returns 4.8% to shareholders annually — split between a 4.1% dividend yield and 0.7% buyback yield. The payout ratio exceeds 100% at 162.7%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery. The earnings yield of 2.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 4.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Payout Ratio | 162.7% | 162.7% | 280.3% | 199.3% | 88.1% | 123.3% | 75.4% | 638.7% | 131.0% | 75.9% | 123.3% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.5% | 345.1% | 226.1% | 328.1% | 612.7% | 509.4% | 654.3% | 93.1% | 170.7% | 486.6% | 309.3% |
| FCF Yield | 10.2% | 1362.2% | 1793.7% | 536.7% | 663.8% | 2074.5% | 1347.7% | 950.7% | 493.4% | 649.9% | 401.9% |
| Buyback Yield | 0.7% | 92.2% | 100.0% | 5.3% | 52.0% | 100.0% | 3.7% | 7.9% | 3.0% | 48.8% | 62.2% |
| Total Shareholder Yield | 4.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Shares Outstanding | — | $3.2B | $3.2B | $3.2B | $3.1B | $3.2B | $3.1B | $3.1B | $1.9B | $1.6B | $1.6B |
Peer Comparison
Compare TAK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TAKYou | $49B | 39.6 | 9.1 | 9.8 | 51.1% | 12.0% | 2.8% | 3.7% | 3.7 |
 NVO | $192B | 12.2 | 9.1 | 43.2 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 AZN | $271B | 26.7 | 15.2 | 23.1 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 SNY | $102B | 18.2 | 10.8 | 10.1 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
 NVS | $281B | 20.5 | 13.7 | 15.9 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 GSK | $102B | 6.9 | 8.6 | 13.3 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
 ABBV | $383B | 91.4 | 15.8 | 21.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 BMY | $110B | 15.7 | 8.9 | 8.6 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 JNJ | $550B | 39.4 | 19.1 | 27.7 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 MRK | $281B | 15.6 | 10.8 | 22.8 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 PFE | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 26 years · Updated daily
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into TAK consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
TAK — Frequently Asked Questions
Quick answers to the most common questions about buying TAK stock.
What is Takeda Pharmaceutical Company Limited's P/E ratio?
Takeda Pharmaceutical Company Limited's current P/E ratio is 39.6x. The historical average is 0.3x. This places it at the 100th percentile of its historical range.
What is Takeda Pharmaceutical Company Limited's EV/EBITDA?
Takeda Pharmaceutical Company Limited's current EV/EBITDA is 9.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 3.2x.
What is Takeda Pharmaceutical Company Limited's ROE?
Takeda Pharmaceutical Company Limited's return on equity (ROE) is 2.8%. The historical average is 8.3%.
Is TAK stock overvalued?
Based on historical data, Takeda Pharmaceutical Company Limited is trading at a P/E of 39.6x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Takeda Pharmaceutical Company Limited's dividend yield?
Takeda Pharmaceutical Company Limited's current dividend yield is 4.08% with a payout ratio of 162.7%.
What are Takeda Pharmaceutical Company Limited's profit margins?
Takeda Pharmaceutical Company Limited has 51.1% gross margin and 12.0% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Takeda Pharmaceutical Company Limited have?
Takeda Pharmaceutical Company Limited's Debt/EBITDA ratio is 3.7x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.